Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff, Alexandre Reuben, Miles C. Andrews, Merrick I. Ross, Isabella C. Glitza, Janice Cormier, Wen Jen Hwu, Hussein A. Tawbi, Sapna P. Patel, Jeffrey E. Lee, Jeffrey E. Gershenwald, Christine N. Spencer, Vancheswaran Gopalakrishnan, Roland Bassett, Lauren Simpson, Rosalind Mouton, Courtney W. Hudgens, Li ZhaoHaifeng Zhu, Zachary A. Cooper, Khalida Wani, Alexander Lazar, Patrick Hwu, Adi Diab, Michael K. Wong, Jennifer L. McQuade, Richard Royal, Anthony Lucci, Elizabeth M. Burton, Sangeetha Reddy, Padmanee Sharma, James Allison, Phillip A. Futreal, Scott E. Woodman, Michael A. Davies, Jennifer A. Wargo
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial'. Together they form a unique fingerprint.